|
| Name of the compound | Chemical class | Source of organisms | Targets | Reference |
|
| Trabectidin | Alkaloids | Tunicate (Ecteinascidia turbinate) | Anticancer effect in breast and prostate and so forth. | [77, 78] |
| Kahalalide F | Cyclic depsipeptide | Mollusk (Elysia rufescens) | Inhibits topoisomerase II in cancer | [81] |
| Heteronemin | Sesterterpene | Sponge (Hyrtios sp.) | Inhibits Leukemia (K562 cells) cancer cells | [82] |
| Tyrindoleninone and 6-bromoisatin | Indole derivative | Mollusk (Dicathais orbita) | Inhibits ovary, granulosa, choriocarcinoma (OVCAR-3, KGN, Jar) cells | [83] |
| Makaluvamine A | Pyrroloquinoline | Sponge (Zyzzya fuliginosa) | Colon cancer (HCT-116 cells) inhibition | [84] |
| Ascididemin | Alkaloid | Mediterranean ascidian (Cystodytes dellechiajei) | Inhibits leukemia (HL-60 and P388) cancer cells | [85, 86] |
| Lamellarin D | Alkaloid | Prosobranch mollusc of the genus (Lamellaria) | Inhibits leukemia cancer cells | [87, 88] |
| Spongistatin 1 | Macrocyclic lactone | Sponges (Spirastrella spinispirulifera and Hyrtios erecta) | Inhibits leukemia
(Jurkat) cancer cells | [89] |
| Chitosan | Polysaccharides | Crabs and shrimp (various species) | Inhibits and induces apoptosis of HeLa cancer cell | [90] |
| Bryostatins | Macrolides | Bryozoan (Bugula neritina) | Inhibits various cancer types and currently used in clinical trials | [91] |
| Eribulin mesylate (E7389) | Macrolide | Halichondria okadai and Axinella family | Microtubule inhibitor and presently used in clinical trials | [93] |
| Aplidin | Cyclic depsipeptide | Ascidian (Aplidium albicans) | Currently in phase II/III clinical trials for solid and hematologic malignancies | [96] |
|
